Impeding Circulating Tumor Cell Reseeding Decelerates Metastatic Progression and Potentiates Chemotherapy

Area of Science:

• Oncology
• Immunology
• Cell Biology

Background:

• Circulating tumor cells (CTCs) are present in metastatic cancer patients but their survival and tumor-seeding mechanisms remain unclear.
• Understanding CTC behavior in circulation is crucial for developing effective cancer therapies.

Purpose of the Study:

• To investigate the role of CX3CR1 in the reseeding of breast CTCs to distant organs.
• To evaluate the therapeutic potential of targeting CX3CR1 in metastatic breast cancer models.

Main Methods:

• Utilized a relevant model of human metastatic breast cancer.
• Investigated the effects of CX3CR1 antagonism on CTC viability, reseeding, and tumor progression.
• Assessed the impact of CX3CR1 targeting on chemotherapy efficacy (doxorubicin and docetaxel).

Main Results:

• CX3CR1 was identified as a key driver for breast CTC reseeding to multiple organs.
• Antagonizing CX3CR1 significantly impaired tumor growth and expansion.
• Therapeutic targeting of CX3CR1 prolonged CTC survival in blood, induced apoptosis, and reduced metastatic reseeding.
• CX3CR1 antagonism enhanced CTC exposure to chemotherapy, showing synergistic effects with doxorubicin and docetaxel.

Conclusions:

• CX3CR1 antagonism represents a promising therapeutic strategy to control metastatic progression in breast cancer.
• Targeting CX3CR1 can contain metastatic spread, prolong survival, and improve response to chemotherapy.